SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery

NCT06300411 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: SRG-514

Sponsor

SURGE Therapeutics